ABPI response to medicines supply contingency plans for 'no deal' Brexit

Mike Thompson, Chief Executive of the ABPI, said: 

“Pharmaceutical companies continue to do everything in their power to make sure that patients get access to medicines whatever the Brexit scenario.    This includes duplicating processes, changing supply routes and stockpiling medicines in line with the Government’s guidance.  However, we have been clear that there are things which are out of our control. 

“Today’s update on potential border delays for six months in a ‘No deal’ scenario is stark.  Stockpiling more medicines is not the solution to this problem.

“While we welcome the Secretary of State’s intention to prioritise the flow of medicines and vaccines, we need the detail.   With just 16 weeks until the UK leaves the EU, we need the Government to take immediate action to open up alternative supply routes between the UK and Europe and tell companies so that they can make plans.”